Life Sciences: Biotech
Investors reconsider genetic therapies
Start-ups funded as technology evolves
Nearly 20 years after the first gene therapy company was started, biotechnology investors are again opening their minds and wallets to the concept of making drugs that fix genetic flaws and cure diseases. (Full article: 1047 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
